{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:14:24Z","timestamp":1779804864724,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital","award":["SD2023005"],"award-info":[{"award-number":["SD2023005"]}]},{"name":"the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital","award":["SD2023005"],"award-info":[{"award-number":["SD2023005"]}]},{"name":"Shanxi Provincial Key Discipline Special Fund","award":["No: 2025051"],"award-info":[{"award-number":["No: 2025051"]}]},{"name":"Shanxi Provincial Key Discipline Special Fund","award":["No: 2025051"],"award-info":[{"award-number":["No: 2025051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51530-x","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:56:43Z","timestamp":1777604203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating CD45\u2009+\u2009CD3+ and CD3\u2009+\u2009CD8+ T-cell markers into nomograms for predicting survival in gastroesophageal junction carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Yubao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"51530_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"51530_CR2","first-page":"124","volume":"18","author":"OM Fitzpatrick","year":"2025","unstructured":"Fitzpatrick, O. M. & Janjigian, Y. Y. Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring, and new targets. Nat. Rev. Gastroenterol. Hepatol. 18, 124\u2013125 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"51530_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift, A. P., Wenker, T. N. & El-Serag, H. B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol. 20 (5), 338\u2013349 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"suppl 5","key":"51530_CR4","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (suppl 5), v38\u2013v49 (2016).","journal-title":"Ann. Oncol."},{"issue":"30","key":"51530_CR5","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1200\/JCO-25-01197","volume":"43","author":"US Grewal","year":"2025","unstructured":"Grewal, U. S., Sanford, N. N. & Brown, T. J. Treat the tumor, spare the esophagus: The case for organ preservation in locally advanced esophageal\/gastroesophageal junction Cancer. J. Clin. Oncol. 43 (30), 3245\u20133248 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"10184","key":"51530_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resettable gastric or gastro-esophageal junction adenocarcinoma (FLOT4): a randomized, phase 2\/3 trial. Lancet 393 (10184), 1948\u20131957 (2019).","journal-title":"Lancet"},{"issue":"2","key":"51530_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/jcm11020311","volume":"11","author":"M Salati","year":"2022","unstructured":"Salati, M. & Spallanzani, A. New horizons for personalized treatment in gastroesophageal cancer. J. Clin. Med. 11 (2), 311 (2022).","journal-title":"J. Clin. Med."},{"issue":"29","key":"51530_CR8","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: Final Analysis of the randomized, phase III KEYNOTE-585 study. J. Clin. Oncol. 43 (29), 3152\u20133159 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"51530_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(18)30108-6","volume":"19","author":"JH Cheong","year":"2018","unstructured":"Cheong, J. H. et al. A predictive test for chemotherapy response in resettable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 19 (5), 629\u2013638 (2018).","journal-title":"Lancet Oncol."},{"issue":"12","key":"51530_CR10","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/annonc\/mdy407","volume":"29","author":"EC Smyth","year":"2018","unstructured":"Smyth, E. C. et al. A seven-gene Signature assay improves prognostic risk stratification of perioperative chemotherapy-treated gastroesophageal cancer patients from the MAGIC trial. Ann. Oncol. 29 (12), 2356\u20132362 (2018).","journal-title":"Ann. Oncol."},{"issue":"35","key":"51530_CR11","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio, F. et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J. Clin. Oncol. 37 (35), 3392\u20133400 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"51530_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao, J. et al. Assessment of Pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7 (6), 895\u2013902 (2021).","journal-title":"JAMA Oncol."},{"issue":"5","key":"51530_CR13","first-page":"669","volume":"19","author":"H Gittleman","year":"2017","unstructured":"Gittleman, H. et al. An independently validated nomogram for individualized survival estimation among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 19 (5), 669\u2013677 (2017).","journal-title":"Neuro Oncol."},{"issue":"1","key":"51530_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12957-023-03097-4","volume":"21","author":"Y Li","year":"2023","unstructured":"Li, Y., Bai, M. & Gao, Y. Prognostic nomograms for gastric carcinoma after D2\u2009+\u2009total gastrectomy to assist decision-making for postoperative treatment: based on Lasso regression. World J. Surg. Oncol. 21 (1), 207 (2023).","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"51530_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12957-024-03481-8","volume":"22","author":"W Qu","year":"2024","unstructured":"Qu, W., Li, L., Ma, J. & Li, Y. Screening high-risk individuals for primary gastric carcinoma: Evaluating overall survival probability score in the presence and absence of lymphatic metastasis post-gastrectomy. World J. Surg. Oncol. 22 (1), 196 (2024).","journal-title":"World J. Surg. Oncol."},{"key":"51530_CR16","doi-asserted-by":"publisher","first-page":"1382818","DOI":"10.3389\/fonc.2024.1382818","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang, J., Li, Y. & Liang, S. Screening high-risk individuals for primary gastric adenocarcinoma: Evaluating progression-free survival probability score in the presence and absence of Rictor expression after gastrectomy. Front. Oncol. 14, 1382818 (2024).","journal-title":"Front. Oncol."},{"issue":"1","key":"51530_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12885-025-13542-0","volume":"25","author":"Y Li","year":"2025","unstructured":"Li, Y., Ma, J. & Cheng, W. Harnessing machine learning and nomogram models to aid predicting progression-free survival for gastric cancer patients post-gastrectomy with deficient mismatch repair(dMMR). BMC Cancer. 25 (1), 141 (2025).","journal-title":"BMC Cancer"},{"key":"51530_CR18","doi-asserted-by":"publisher","first-page":"643261","DOI":"10.3389\/fonc.2021.643261","volume":"11","author":"Q Guo","year":"2021","unstructured":"Guo, Q. et al. Prognostic nomogram for postoperative patients with gastroesophageal junction cancer of no distant metastasis. Front. Oncol. 11, 643261 (2021).","journal-title":"Front. Oncol."},{"key":"51530_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/jcm11185439","volume":"11","author":"M Salati","year":"2022","unstructured":"Salati, M. et al. Development and multicenter validation of a novel immune-inflammation-based nomogram to predict Survival in Western Resectable gastric and gastroesophageal junction adenocarcinoma (GEA): The NOMOGAST. J. Clin. Med. 11, 18 (2022).","journal-title":"J. Clin. Med."},{"issue":"12","key":"51530_CR20","doi-asserted-by":"publisher","first-page":"108658","DOI":"10.1016\/j.ejso.2024.108658","volume":"50","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. Risk stratification models incorporating oxidative stress factors to predict survival and recurrence in patients with gastric cancer after radical gastrectomy: A real-world multicenter study. Eur. J. Surg. Oncol. 50 (12), 108658 (2024).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"51530_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4240\/wjgs.v16.i2.357","volume":"16","author":"ZR Chen","year":"2024","unstructured":"Chen, Z. R. et al. Risk stratification in gastric cancer lung metastasis: Utilizing an overall survival nomogram and comparing it with previous staging. World J. Gastrointest. Surg. 16 (2), 357\u2013381 (2024).","journal-title":"World J. Gastrointest. Surg."},{"issue":"4","key":"51530_CR22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jmri.28621","volume":"58","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Risk stratification and overall survival prediction in advanced gastric cancer patients based on whole-volume MRI radiomics. J. Magn. Reson. Imaging. 58 (4), 1161\u20131174 (2023).","journal-title":"J. Magn. Reson. Imaging"},{"issue":"9","key":"51530_CR23","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1007\/s00261-021-03049-0","volume":"46","author":"C Feng","year":"2021","unstructured":"Feng, C. et al. Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer. Abdom. Radiol. (NY). 46 (9), 4079\u20134089 (2021).","journal-title":"Abdom. Radiol. (NY)"},{"issue":"5","key":"51530_CR24","doi-asserted-by":"publisher","first-page":"e28620","DOI":"10.1097\/MD.0000000000028620","volume":"101","author":"Y Li","year":"2022","unstructured":"Li, Y. & Zhao, H. Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients. Med. (Baltim). 101 (5), e28620 (2022).","journal-title":"Med. (Baltim)."},{"issue":"1","key":"51530_CR25","first-page":"215","volume":"20","author":"Y Ding","year":"2020","unstructured":"Ding, Y. et al. Identification of genes associated with gastric cancer survival and construction of a nomogram to improve risk stratification for patients with gastric cancer. Oncol. Lett. 20 (1), 215\u2013225 (2020).","journal-title":"Oncol. Lett."},{"issue":"6349","key":"51530_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts the response of solid tumors to PD-1 blockade. Science 357 (6349), 409\u2013413 (2017).","journal-title":"Science"},{"issue":"4","key":"51530_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26 (4), 566\u2013576 (2020).","journal-title":"Nat. Med."},{"issue":"6","key":"51530_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao, J. et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7 (6), 895\u2013902 (2021).","journal-title":"JAMA Oncol."},{"issue":"5","key":"51530_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker, K. et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Ann. Surg. 253 (5), 934\u2013939 (2011).","journal-title":"Ann. Surg."},{"issue":"6","key":"51530_CR30","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1245\/s10434-011-2165-6","volume":"19","author":"K Fujitani","year":"2012","unstructured":"Fujitani, K. et al. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann. Surg. Oncol. 19 (6), 1936\u20131943 (2012).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"51530_CR31","first-page":"123","volume":"74","author":"R Mehta","year":"2024","unstructured":"Mehta, R. et al. Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring. CA Cancer J. Clin. 74 (2), 123\u2013131 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"51530_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12885-025-13810-z","volume":"25","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to double invasion: an analytical approach utilizing lasso-cox regression. BMC Cancer. 25 (1), 381 (2025).","journal-title":"BMC Cancer"},{"issue":"5","key":"51530_CR33","doi-asserted-by":"publisher","first-page":"e28620","DOI":"10.1097\/MD.0000000000028620","volume":"101","author":"Y Li","year":"2022","unstructured":"Li, Y. & Zhao, H. Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients. Med. (Baltim). 101 (5), e28620 (2022).","journal-title":"Med. (Baltim)."},{"issue":"1","key":"51530_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s40001-025-02761-7","volume":"30","author":"Z Hao","year":"2025","unstructured":"Hao, Z. et al. Harnessing the machine learning and nomogram models: elevating prognostication in nonmetastatic gastric cancer with double invasion for personalized patient care. Eur. J. Med. Res. 30 (1), 517 (2025).","journal-title":"Eur. J. Med. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51530-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:57:38Z","timestamp":1779803858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51530-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51530"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51530-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We consulted extensively with the Ethics Committee of Shanxi Cancer Hospital and obtained ethical approval (No. 2022JC23). The relevant guidelines and regulations were followed in all methods. The ethical standards of our institutional research committee were adhered to in all procedures conducted in studies involving human participants. Written informed consent was obtained from the patient for publication and for any accompanying images\n                      32\u201334\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"16307"}}